CN102512488A - Application of kudzu root in preparation of medicament for preventing and treating osteoporosis - Google Patents
Application of kudzu root in preparation of medicament for preventing and treating osteoporosis Download PDFInfo
- Publication number
- CN102512488A CN102512488A CN2012100073249A CN201210007324A CN102512488A CN 102512488 A CN102512488 A CN 102512488A CN 2012100073249 A CN2012100073249 A CN 2012100073249A CN 201210007324 A CN201210007324 A CN 201210007324A CN 102512488 A CN102512488 A CN 102512488A
- Authority
- CN
- China
- Prior art keywords
- radix puerariae
- preventing
- treating osteoporosis
- preparation
- osteoporosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of kudzu root in the preparation of a medicament for preventing and treating osteoporosis. A large number of experiments show that the kudzu root has the effects of increasing the bone mineral density and increasing serum calcium content and phosphorus content in vivo for the first time, and the aim of preventing and treating osteoporosis is fulfilled.
Description
Technical field
The present invention relates to the new purposes of Radix Puerariae.
Background technology
Osteoporosis (osteoporosis) is a kind of systemic osteopathia; It is characterized in that the bone amount descends and the fine structure of bone destroys; The fragility that shows as bone increases, thereby the danger of fracture greatly increases, even also fracture easily under slight wound or the atraumatic situation.Osteoporosis is a kind of chronic disease due to multifactor.Before fracture takes place, there is not special clinical manifestation usually.The women is more than the male for this disease, is common in postmenopausal women and old people.Along with the increase of China's aging population, the osteoporosis sickness rate is in ascendant trend, all is a health problem that merits attention in the China and even the whole world.
The danger that prevents or reduce further bone loss, bone mass increasing and reduction to fracture is the main purpose of clinical treatment osteoporosis.The Prevention and Treatment of Osteoporosis disease drug has a variety of; Can be divided into two types according to mechanism of action; The one, suppress the bone resorption medicine, mainly contain estrogen (estrogen), calcitonin (calcitonin), diphosphonates (bisphosphonates), ipriflavone (ipriflavone) etc.; The 2nd, short bone formation medicine mainly contains bone mineralizer (calcium salt, vitamin D and derivant thereof), androgens (androgen), growth hormone (GH), fluoride (fluoride), protein anabolic hormone (anabolic steroids) etc.
The effect of Radix Puerariae:
The effect of 1 pair of smooth muscle: the daidzein in the Radix Puerariae has the anti-acetylcholine effect, can obviously shrink smooth muscle, is considered to the main component of Radix Puerariae spasmolysis.
The effect of 2 pairs of coronary circulations: Radix Puerariae water decoction, pure extractum, total flavones and puerarin all have the effect of tangible expansion coronary vasodilator, and the hat blood flow is increased, and vascular resistance reduces.
3 pairs of myocardial infarctions and ARR effect: the arrhythmia effect that Radix Puerariae alcohol extractum, daidzein and puerarin all have tangible antagonism aconitine and barium chloride to bring out; Puerarin can also shorten obviously that chlorine is walked back and forth, the cardiac arrhythmia induced by epinephrine in rabbits time; Puerarin can obviously dwindle myocardial infarct size, is considered to a kind of receptor, blocker.
The influence of the 4 pairs of cardiac functions and myocardial metabolism: Radix Puerariae total flavones and puerarin can decreased heart rate, reduce the heart total peripheral resistance, reduce myocardial oxygen consumption; Improving myocardium work efficiency. puerarin can also obviously reduce the generation of the myocardium lactic acid that ischemia causes, improves the metabolism of infarcted myocardium.
5 pairs of blood pressures and peripheral vascular effect: total Pueraria lobota ketone of Radix Puerariae and puerarin can make plasma renin activity and angiotensin significantly reduce; Blood pressure drops. puerarin improves significantly to microcirculation disturbance, mainly shows as the amplitude and the local little blood flow of raising that increase the blood capillary motion; Radix Puerariae total flavones has the effect of obvious expansion of cerebral vascular, improves brain microcirculation and peripheral circulation. and it is reported that puerarin can also improve the retinal vessel end retardance state of unit slightly, thereby improve visual function.
6 anticoagulant effects: puerarin can suppress that adenosine diphosphate (ADP) (ADP) is induced and the platelet aggregation of 5-HT (5-hydroxy tryptamine) and the humans and animals of ADP combined induction; In addition, puerarin can also obviously suppress the release by 5-HT in the platelet of thrombin induction, has anti-thrombosis function.
7 hypoglycemic effects: puerarin can have certain blood sugar lowering ability to adrenolytic blood glucose increasing effect.
The influence of 8 pairs of body temperature: Radix Puerariae total flavones causes fervescence to endotoxin to have and changes lasting and the obvious cooling effect is usually used in all diseases of fever caused by exogenous pathogens clinically.
The influence of 9 pairs of memories: Radix Puerariae total flavones and ethanol extract can improve rat cerebral cortex and Hippocampus acetyl choline content; And it is active to reduce the Hippocampus acetylcholine transferase; Resist the rat that eastern Liang alkali imitated and remember acquired obstacle, this explanation, the have some improvement ability of learning and memory of Radix Puerariae tool.
Not seeing has the bibliographical information Radix Puerariae to be applied in the treatment osteoporosis.
Summary of the invention
The purpose of this invention is to provide Radix Puerariae and prevent and treat the new purposes of osteoporosis disease medicament in preparation.
Above-mentioned purpose of the present invention is achieved through following technical scheme:
The present invention finds that through a large amount of experiments Radix Puerariae or its water extract as raw material, can be prepared into oral any dosage form by the conventional formulation method, is used for Prevention and Treatment of Osteoporosis.
Compared with prior art, the present invention has following beneficial effect:
The present invention is directed to osteoporotic pathogenesis and clinical symptoms; Through a large amount of experiments; Find to use the medicine that Radix Puerariae prepares Prevention and Treatment of Osteoporosis, can play bone density improving, improve serum calcium, phosphorus content effect in the body, thereby reach the purpose of Prevention and Treatment of Osteoporosis.
The specific embodiment
Embodiment 1
1 experimental technique
The SD male rat at 60 3 monthly ages is divided into 5 groups at random, and promptly matched group, model group, administration high dose group and middle dose groups, low dosage are three groups.Every group 12.All the other four groups of rat skin lower injection first are sprinkled Buddhist nun 3.5mg/kg except that matched group, every day 1 subcutaneous injection, continuous 60 days.The administration group is irritated stomach simultaneously and is given medicine of the present invention, and Radix Puerariae decocting liquid adopts conventional decocting method preparation, and the simmer down to respective concentration, and decocting liquid various dose group comprises low dose group (10g/kg), middle dose groups (20g/kg), high dose group (40g/kg); Gastric infusion is respectively organized in medication, and all the other each groups are irritated the normal saline of clothes equivalent, experiment successive administration totally 60 days.Measure bone density (BMD) after 60 days, serum calcium, serum paraoxonase level.
2 experimental results
The experiments result of laboratory animal sees the following form 1 after the administration.
Group | The whole province's bone density | Phosphorus (mmol/L) | Calcium (mmol/L) |
Matched group | 0.321±0.054 | 2.356±0.112 | 2.132±0.062 |
Model group | 0.180±0.052* | 1.752±0.102* | 1.541±0.092* |
Low dose group | 0.232±0.043** | 1.804±0.132 | 1.631±0.093** |
Middle dose groups | 0.250±0.043** | 1.952±0.083** | 1.751±0.082** |
High dose group | 0.289±0.049** | 2.210±0.132** | 1.926±0.082** |
* representative is compared with matched group
P<0.05; The * representative is compared with model group,
P<0.05
Above-mentioned experimental result shows: model group and matched group compare, all significantly reductions of bone density (
P<0.05), show that experimental animal model prepares successfully; Each dose groups serum calcium of administration, phosphorus content, whole body bone density content all raise to some extent, above-mentioned each index of middle and high dose groups and model group comparison, difference have the significance meaning (
P<0.05), explain Radix Puerariae can control agent in content of mineral substances, bone density improving has preventive and therapeutic effect to osteoporosis.
Claims (2)
1. the application of Radix Puerariae in preparation control medicine for treating osteoporosis.
2. the application of Radix Puerariae water extract in preparation control medicine for treating osteoporosis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100073249A CN102512488A (en) | 2012-01-12 | 2012-01-12 | Application of kudzu root in preparation of medicament for preventing and treating osteoporosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100073249A CN102512488A (en) | 2012-01-12 | 2012-01-12 | Application of kudzu root in preparation of medicament for preventing and treating osteoporosis |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102512488A true CN102512488A (en) | 2012-06-27 |
Family
ID=46283741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012100073249A Pending CN102512488A (en) | 2012-01-12 | 2012-01-12 | Application of kudzu root in preparation of medicament for preventing and treating osteoporosis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102512488A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103816211A (en) * | 2012-11-16 | 2014-05-28 | 邢秋苓 | Puerarin extract capable of suppressing formation of osteoclast |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1321500A (en) * | 2001-04-23 | 2001-11-14 | *** | Method for preventing and curing diseases by using kakonein preparation |
-
2012
- 2012-01-12 CN CN2012100073249A patent/CN102512488A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1321500A (en) * | 2001-04-23 | 2001-11-14 | *** | Method for preventing and curing diseases by using kakonein preparation |
Non-Patent Citations (1)
Title |
---|
孙玉明等: "葛根对原发性骨质疏松症患者临床症状影响的研究", 《中国中医骨伤科杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103816211A (en) * | 2012-11-16 | 2014-05-28 | 邢秋苓 | Puerarin extract capable of suppressing formation of osteoclast |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1209121C (en) | Heart-strengthening and blood circulation-promoting liquid medicine for treating heart diseases | |
CN100387145C (en) | Gingko tea preparation and production process thereof | |
CN103816280B (en) | Traditional Chinese medicine composition for treating myocardial infarction and application of traditional Chinese medicine composition | |
CN101780227B (en) | Traditional Chinese medicine composition for treating acute stroke and preparation method thereof | |
CN101822789B (en) | Hypotensor treating essential hypertension | |
CN102908513B (en) | Application of traditional Chinese medicine composition in medicine for treating arrhythmia | |
CN102512488A (en) | Application of kudzu root in preparation of medicament for preventing and treating osteoporosis | |
CN103479754A (en) | Hypotensive drug and preparation method thereof | |
CN100441195C (en) | Medicinal composition containing safflower total flavone and its preparation process and usage | |
CN101804075B (en) | Application of starfishes to preparation of medicament for treating osteoporosis | |
CN101361797B (en) | Traditional Chinese medicine pressure-reduction insoles | |
CN102266481B (en) | Chinese medicinal preparation for treating chronic cerebral circulation insufficiency | |
CN102716231B (en) | A kind of Chinese medicine composition and application thereof for the treatment of brain injury and cerebral edema | |
CN102210807B (en) | Application of traditional Chinese medicine composition in preparation of medicaments for treating angina pectoris | |
CN101199568A (en) | Medicament compound for treating cardiovascular disease and preparing method thereof | |
CN1262942A (en) | Intravenous injection medicine for curing ischemic cerebrovascular disease and its preparing method | |
CN1216618C (en) | A TCM compound recipe notoginseng capsule and method for preparing the same | |
CN102416036B (en) | Traditional Chinese medicinal compositions for preventing and treating ventricular reconstruction due to coronary heart disease and use thereof | |
CN101810701A (en) | Medicinal tea for preventing cerebral apoplexy | |
CN105687567A (en) | Preparation for preventing and treating diarrhea caused by chemotherapy and preparation method of preparation | |
CN104825627A (en) | Oral gel preparation for treating angina pectoris and preparation method thereof | |
CN104906495A (en) | Hypertension symptom improvement medicine mainly using rhodiola rosea | |
CN106138795A (en) | Chinese medicine composition for the treatment of premature beat and preparation method thereof | |
CN104524313A (en) | Traditional Chinese medicine preparation for treating sick sinus syndrome | |
CN103083545B (en) | The purposes of Huo-Lisu oral liquor synergistic tandospirone or its salts for treating anxiety |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120627 |